Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIV postexposure prophylaxis with darunavir/ritonavir (PEPDar)
2011-001303-13Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of darunavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Early discontinuation rate of randomized HIV PEP. Started Jun 2011; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2011-001303-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001303-13.